Pablo J. Cagnoni net worth and biography

Pablo Cagnoni Biography and Net Worth

President, Head of Research and Development of Incyte

Pablo J. Cagnoni, M.D., joined Incyte in 2023 as President, Head of Research & Development. In his role, Dr. Cagnoni oversees Incyte’s research and development efforts across its portfolio of programs in Hematology, Oncology and Inflammation and Autoimmunity, including Dermatology.

Prior to joining Incyte, Dr. Cagnoni served as the Chief Executive Officer of Laronde, a company dedicated to the development of a new type of translatable ribonucleic acid (RNA) called endless RNA (eRNA), and held leadership roles at Rubius Therapeutics, Tizona Therapeutics, Onyx Pharmaceuticals and Novartis Oncology. Throughout his career as a pharmaceutical executive and oncologist, Dr. Cagnoni has advanced the development of breakthrough treatments, playing a key role in the development, approval and commercialization of more than 20 life-changing medicines.

Dr. Cagnoni earned his medical degree from the University of Buenos Aires School of Medicine. He completed his fellowship in Hematology and Oncology at the Mount Sinai Medical Center, New York, and a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center.

What is Pablo J. Cagnoni's net worth?: The estimated net worth of Pablo J. Cagnoni is at least $25.52 million as of April 17th, 2026. Dr. Cagnoni owns 262,692 shares of Incyte stock worth more than $25,517,901 as of May 4th. This net worth approximation does not reflect any other investments that Dr. Cagnoni may own. Learn More about Pablo J. Cagnoni's net worth.
How do I contact Pablo J. Cagnoni?: The corporate mailing address for Dr. Cagnoni and other Incyte executives is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. Incyte can also be reached via phone at (302) 498-6700 and via email at [email protected]. Learn More on Pablo J. Cagnoni's contact information.
Has Pablo J. Cagnoni been buying or selling shares of Incyte?: During the last quarter, Pablo J. Cagnoni has sold $1,801,365.50 of Incyte stock. Most recently, Pablo J. Cagnoni sold 18,667 shares of the business's stock in a transaction on Friday, April 17th. The shares were sold at an average price of $96.50, for a transaction totalling $1,801,365.50. Following the completion of the sale, the insider now directly owns 262,692 shares of the company's stock, valued at $25,349,778. Learn More on Pablo J. Cagnoni's trading history.
Who are Incyte's active insiders?: Incyte's insider roster includes Pablo Cagnoni (President, Head of Research and Development), Sheila Denton (EVP), Dashyant Dhanak (EVP), Jonathan Dickinson (EVP), Wendy Dixon (Director), Barry Flannelly (EVP), Lee Heeson (EVP), Herve Hoppenot (CEO & Chairman), Mohamed Issa (EVP), Vijay Iyengar (EVP), Michael Morrissey (EVP), Maria Pasquale (EVP), Steven Stein (EVP), Paula Swain (EVP), Thomas Tray (Insider), and Wenquing Yao (EVP). Learn More on Incyte's active insiders.
Are insiders buying or selling shares of Incyte?: During the last twelve months, insiders at the biopharmaceutical company sold shares 21 times. They sold a total of 192,884 shares worth more than $17,312,812.71. The most recent insider tranaction occured on April, 17th when insider Pablo J Cagnoni sold 18,667 shares worth more than $1,801,365.50. Insiders at Incyte own 17.8% of the company. Learn More about insider trades at Incyte.
Information on this page was last updated on 4/17/2026.

Pablo J. Cagnoni Insider Trading History at Incyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/17/2026	Sell	18,667	$96.50	$1,801,365.50	262,692
3/17/2026	Sell	18,667	$94.24	$1,759,178.08	234,800

Pablo J. Cagnoni Buying and Selling Activity at Incyte

Incyte Company Overview

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Today's Range

Now: $97.14

$96.34

$97.60

50 Day Range

MA: $95.71

$90.30

$101.32

2 Week Range

Now: $97.14

$57.77

$112.29

Volume

1,018,029 shs

Average Volume

1,761,494 shs

Market Capitalization

$19.41 billion

P/E Ratio

13.72

Dividend Yield

N/A

Beta

0.79